Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

41.42 +0.89 (+2.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,609,740
Open 40.58
Bid (Size) 34.91 (1)
Ask (Size) 44.00 (4)
Prev. Close 40.53
Today's Range 40.02 - 41.82
52wk Range 31.52 - 54.56
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace

Performance

YTD
-14.01%
-14.01%
1 Month
+5.29%
+5.29%
3 Month
-11.53%
-11.53%
6 Month
-15.80%
-15.80%
1 Year
-14.69%
-14.69%

More News

Read More
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
Via Benzinga
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Via Benzinga
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
Via Benzinga
Topics Stocks
Exposures US Equities
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.